Indivior Pharmaceuticals, Inc.
INDV evidence brief
What we can confirm
- BioSniper Score:
- 5.2 / 10
- Market Cap:
- $4.05B
- Lead Asset:
- sublocade (Phase 4)
What it means
What to watch
Prepared research question
What matters most for INDV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INDV
Indivior Pharmaceuticals, Inc. (INDV) is a biopharmaceutical company focused on treatments for opioid use disorder, with its lead product SUBLOCADE driving strong revenue growth and profitability, while facing pipeline setbacks and legal risks.
Key risk: Negative equity
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 6 clinical trials · 4 catalysts for Indivior Pharmaceuticals, Inc..
Indivior Pharmaceuticals, Inc. (INDV) is a biopharmaceutical company focused on treatments for opioid use disorder, with its lead product SUBLOCADE driving strong revenue growth and profitability, while facing pipeline setbacks and legal risks.
- Total net revenue increased 4% year-over-year to $1.24 billion in 2025, driven by SUBLOCADE net revenue growth of 13% to a record $856 million [sec · filed 2026-03-27].
- GAAP net income was $122 million in Q2 2026, with record quarterly Adjusted EBITDA of $186 million, up 111% year-over-year [news · published 2026-08-03].
- Cash & equivalents were $222.0 million as of 2026-06-30, with total debt of $487.0 million and shareholders' equity of -$208.0 million [latest reported financials].
- The company resolved a legacy U.S. Department of Justice matter by paying off the remaining outstanding obligation, removing a significant liability [sec · filed 2026-03-27].
- A $400 million share repurchase program was authorized, with approximately 4.7 million shares repurchased in Q2 2026 for $175 million [news · published 2026-08-03].
What works
- SUBLOCODE net revenue grew 13% year-over-year to a record $856 million in 2025, driven by label enhancements and improved commercial execution [sec · filed 2026-03-27].
- Adjusted EBITDA margin improved by 500 basis points to 35% in 2025, reflecting strong profitability and cost discipline [sec · filed 2026-03-27].
- The company generated record quarterly GAAP net income of $122 million in Q2 2026, up significantly year-over-year [news · published 2026-08-03].
- Resolution of the legacy DOJ matter strengthened the balance sheet and removed a reputational overhang [sec · filed 2026-03-27].
What to weigh
- Shareholders' equity was negative at -$208.0 million as of 2026-06-30, indicating accumulated deficits exceeding equity [latest reported financials].
- Total debt stood at $487.0 million as of 2026-06-30, representing a significant financial obligation [latest reported financials].
- Pipeline setbacks and legal risks add caution to the company's outlook, according to a news analysis [news · published 2026-08-21].
- The company's reliance on SUBLOCADE for growth creates concentration risk, with pipeline candidates still in early phases [pipeline].
From the filings
Quoted directly from source documents.
Record quarterly GAAP net income in Q2 2026
“Record Quarterly GAAP Net Income of $122 Million”
News · August 3, 2026
Resolution of legacy DOJ matter
“Resolved the legacy U.S. Department of Justice ("DOJ") matter by paying off the remaining outstanding obligation”
SEC filings · March 27, 2026
Catalyst timeline
- 2028-02-13 · Patent_Expiry · RISPERIDONE — Patent expiry for NDA210655 may open market to generic competition.
- 2030-03-26 · Patent_Expiry · BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE — Patent expiry for NDA022410 may affect related product exclusivity.
- 2038-06-22 · Patent_Expiry · BUPRENORPHINE — Patent expiry for NDA209819 may impact buprenorphine-based products.
- 2042-08-04 · Patent_Expiry · NALMEFENE HYDROCHLORIDE — Patent expiry for NDA217470 may affect nalmefene-related products.
Risks & what to watch (4)›
Key risks
- Negative equity — Shareholders' equity of -$208.0M as of 2026-06-30 indicates accumulated deficits exceed equity [latest reported financials].
- High debt level — Total debt of $487.0M as of 2026-06-30 represents a significant financial obligation [latest reported financials].
- Pipeline setbacks — Pipeline setbacks and legal risks add caution to the company's outlook [news · published 2026-08-21].
- Product concentration — Heavy reliance on SUBLOCADE for revenue growth creates concentration risk [pipeline].
What to watch
- SUBLOCODE net revenue growth trajectory and market share in the opioid use disorder treatment space [news · published 2026-08-03].
- Execution of the $400 million share repurchase program and its impact on shareholder value [sec · filed 2026-03-27].
- Potential business development or merger opportunities, such as the proposed Supernus merger [news · published 2026-08-21].
- Progress of pipeline candidate INDV-6001, which entered Phase 2 in September 2024 [catalyst].
Sources: Catalysts · News · Pipeline · SEC filings · Generated October 4, 2026 · How we verify sources →
Run Indivior Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Indivior Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income $122M
No tracked pipeline phase
1 candidate
4 upcoming, next in ~488d
2 buys · 3 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 12.4%
- Days to cover
- 7.2
- Shares short
- 12,824,697
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INDV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Indivior Pharmaceuticals, Inc.?
Indivior Pharmaceuticals, Inc. (INDV) is a biopharmaceutical company focused on treatments for opioid use disorder, with its lead product SUBLOCADE driving strong revenue growth and profitability, while facing pipeline setbacks and legal risks.
What is Indivior Pharmaceuticals, Inc.'s lead drug candidate?
Indivior Pharmaceuticals, Inc.'s most advanced tracked candidate is sublocade (Phase 4) for Moderate to Severe Opioid Use Disorder; Opioid-use Disorder; Opioid Use Disorder, Severe.
What is Indivior Pharmaceuticals, Inc.'s next catalyst?
Indivior Pharmaceuticals, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA210655" — expected February 13, 2028.
Who is the CEO of Indivior Pharmaceuticals, Inc.?
Mr. Joseph J. Ciaffoni is the chief executive officer of Indivior Pharmaceuticals, Inc. (INDV).
Where is Indivior Pharmaceuticals, Inc. headquartered?
Indivior Pharmaceuticals, Inc. (INDV) is headquartered in North Chesterfield, VA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.